Advertisement

Topics

US FDA grants breakthrough therapy designation to Imfinzi for patients with locally─advanced unresectable NSCLC

07:26 EDT 1 Aug 2017 | PharmaBiz

AstraZeneca and MedImmune, its global biologics research and development arm, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Imfinzi (durvalumab)

Original Article: US FDA grants breakthrough therapy designation to Imfinzi for patients with locally─advanced unresectable NSCLC

NEXT ARTICLE

More From BioPortfolio on "US FDA grants breakthrough therapy designation to Imfinzi for patients with locally─advanced unresectable NSCLC"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...